$8.55
+0.07(0.83%)
Mkt Cap $49M
$7.14
$16.10
52-Week Range
At a Glance
AI-generatedXilio Therapeutics, Inc., a clinical-stage biotech firm, reported total revenue of $43.8 million for FY 2025, a significant increase from $6.3 million in FY 2024, driven by collaboration and license revenue from agreements with AbbVie ($20.1 million) and Gilead ($23.6 million), including milestones.
8-K
Xilio Therapeutics announced fourth quarter and full year 2025 financial results on March 23, 2026, reporting collaboration and license revenue of $13.7 million for Q4 and net income of $10.4 million, alongside a cash position of $137.5 million as of December 31, 2025. The company provided pipeline updates on XTX501 and masked T cell engagers, with cash runway extended through the end of 2027.$49M
Market Cap
$3M
Revenue
—
Net Income
Employees64
Fundamentals
How The Business Makes Money
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001840233
ISINUS98422T1007
CUSIP98422T100
Phone617 430 4680
Address828 Winter Street, Waltham, MA, 02451, US
SEC EDGAR